Press Release | Thu Oct 24, 2013 6:15am EDT

FDA Grants Breakthrough Therapy Designation to cPMP Replacement Therapy for Patients with Molybdenum Cofactor Deficiency (MoCD) Type A

* Reuters is not responsible for the content in this press release.